{
    "id": 1638,
    "fullName": "KIT D820Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT D820Y lies within the protein kinase domain of the Kit protein (UniProt.org). D820Yresuts in constitutive phosphorylation of Kit and is transforming in cell culture (PMID: 19035443, PMID: 11984533), and has also been identified as a secondary mutation associated with imatinib-resistance (PMID: 18488160).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 660,
                    "pubMedId": 11984533,
                    "title": "Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11984533"
                },
                {
                    "id": 7082,
                    "pubMedId": 18488160,
                    "title": "Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18488160"
                },
                {
                    "id": 661,
                    "pubMedId": 19035443,
                    "title": "Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19035443"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "D820Y",
    "createDate": "09/09/2014",
    "updateDate": "09/14/2018",
    "referenceTranscriptCoordinates": {
        "id": 136110,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54733166G>T",
        "cDna": "c.2458G>T",
        "protein": "p.D820Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12287,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12289,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) failed to inhibit MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12290,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cell lines harboring KIT D820Y in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 6429,
                "therapyName": "SEL201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8616,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment resulted in stable disease with 27% reduction in target lesions at 4 weeks in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6700,
                    "pubMedId": 20372153,
                    "title": "Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20372153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).",
            "molecularProfile": {
                "id": 28311,
                "profileName": "KIT V559D KIT D820Y"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 676,
                    "pubMedId": 17699867,
                    "title": "Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17699867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).",
            "molecularProfile": {
                "id": 28311,
                "profileName": "KIT V559D KIT D820Y"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 676,
                    "pubMedId": 17699867,
                    "title": "Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17699867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture, with increased potency compared to Sprycel (dasatinib) or Nexavar (sorafenib) (PMID: 17699867).",
            "molecularProfile": {
                "id": 28311,
                "profileName": "KIT V559D KIT D820Y"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 676,
                    "pubMedId": 17699867,
                    "title": "Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17699867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14618,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KIT D820G and KIT D820Y were identified as secondary mutations in a patient with gastrointestinal stromal tumor harboring a primary KIT V555_L576del mutation, who developed resistance to Gleevec (imatinib) (PMID: 18488160).",
            "molecularProfile": {
                "id": 30369,
                "profileName": "KIT V555_L576del KIT D820G KIT D820Y"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7082,
                    "pubMedId": 18488160,
                    "title": "Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18488160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14624,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KIT D820Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT V569_L576del and KIT Y553S mutations, who developed resistance to Gleevec (imatinib) (PMID: 18488160).",
            "molecularProfile": {
                "id": 30374,
                "profileName": "KIT Y553S KIT V556_T574del KIT D820Y"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7082,
                    "pubMedId": 18488160,
                    "title": "Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18488160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18612,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Ripretinib (DCC-2618) decreased circulating tumor DNA, resulted in stable disease lasting over 21 months in a patient with gastrointestinal stromal tumor harboring a primary KIT Y568_L576delinsCV mutation and two acquired resistance mutations, KIT D816E and KIT D820Y (PMID: 31085175; NCT02571036).",
            "molecularProfile": {
                "id": 33485,
                "profileName": "KIT Y568_L576delinsCV KIT D816E KIT D820Y"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1650,
            "profileName": "KIT D820Y",
            "profileTreatmentApproaches": [
                {
                    "id": 1475,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT D820Y"
                }
            ]
        },
        {
            "id": 28311,
            "profileName": "KIT V559D KIT D820Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30369,
            "profileName": "KIT V555_L576del KIT D820G KIT D820Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30374,
            "profileName": "KIT Y553S KIT V556_T574del KIT D820Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33485,
            "profileName": "KIT Y568_L576delinsCV KIT D816E KIT D820Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136111,
            "transcript": "XM_005265741",
            "gDna": "chr4:g.54733166G>T",
            "cDna": "c.2458G>T",
            "protein": "p.D820Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136110,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54733166G>T",
            "cDna": "c.2458G>T",
            "protein": "p.D820Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}